Aimovig (Erenumab-aooe) for Migraine | MyMigraineTeam

Connect with others who understand.

sign up Log in
About MyMigraineTeam
Powered By

Aimovig is approved by the Food and Drug Administration (FDA) to prevent migraine in adults. Aimovig is also referred to by its drug name, Erenumab-aooe.

Aimovig is a biologic drug – a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Aimovig is also the first member of a new class of drugs called calcitonin gene-related peptide receptor (CGRP-R) antagonists. Aimovig is believed to work by interfering with CGRP, a substance that dilates blood vessels and contributes to pain signals and inflammation.

How do I take it?
Prescribing information states that Aimovig is administered as a subcutaneous injection once a month.

Aimovig comes in prefilled, single-dose formats as a syringe or an autoinjector.

Side effects
The FDA-approved label for Aimovig lists common side effects including constipation and injection site reactions.

Because Aimovig is a new drug, its long-term effects are not yet known.

For more details about this treatment, visit: – Amgen

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in